Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eEF-2K siRNA
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intraperitoneal, Intratumoral
01
Overview
eEF-2K siRNA is a research-stage small interfering RNA (siRNA) therapeutic designed to silence the expression of eukaryotic elongation factor 2 kinase (eEF2K). eEF2K is a calcium/calmodulin-dependent serine/threonine kinase that is frequently overexpressed in various malignancies, including triple-negative breast cancer (TNBC), pancreatic cancer, glioblastoma, and melanoma. By targeting eEF2K mRNA for degradation, the siRNA inhibits the phosphorylation of eEF2, thereby disrupting protein synthesis elongation and inducing apoptosis or autophagy-mediated cell death. Preclinical studies have utilized neutral nanoliposomes (such as DOPC) for systemic delivery, demonstrating significant antitumor activity and sensitization to chemotherapy.
- Other names
- EEF2K siRNAEEF-2K siRNAEEF 2K siRNAeEF2K-siRNAeEF-2K-siRNAeEF 2K-siRNAsi-eEF2Ksi-eEF-2Ksi-eEF 2KsiRNA targeting eEF2K
02
Targets
EEF2K (Eukaryotic elongation factor 2 kinase)
Beyond the preview
Go deeper on eEF-2K siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eEF-2K siRNA.